2,093 Shares in Amgen Inc. $AMGN Bought by Canandaigua National Trust Co of Florida

Canandaigua National Trust Co of Florida bought a new position in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 2,093 shares of the medical research company’s stock, valued at approximately $882,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Wellington Altus USA Inc. grew its stake in Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the period. Tower View Wealth Management LLC lifted its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new position in Amgen during the second quarter valued at $36,000. Evergreen Advisors LLC bought a new stake in shares of Amgen during the 1st quarter valued at $37,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in shares of Amgen during the 4th quarter valued at $44,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 2.6%

Shares of AMGN traded up $10.48 during trading hours on Wednesday, hitting $413.08. The company had a trading volume of 2,236,544 shares, compared to its average volume of 2,758,837. The stock has a market capitalization of $223.32 billion, a price-to-earnings ratio of 25.67, a P/E/G ratio of 2.91 and a beta of 0.41. The firm has a fifty day moving average price of $411.44 and a 200-day moving average price of $371.01. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is presently 62.65%.

Insider Activity at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMGN. Argus increased their price target on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Cantor Fitzgerald reissued a “neutral” rating on shares of Amgen in a research note on Monday. HSBC cut shares of Amgen from a “buy” rating to a “hold” rating and cut their price objective for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Jefferies Financial Group reaffirmed a “hold” rating and set a $410.00 target price on shares of Amgen in a research note on Wednesday, September 23rd. Finally, Piper Sandler boosted their price target on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $385.79.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported results from a clinical trial involving a treatment for Sjögren’s disease. The update appears to have supported the stock by providing investors with additional visibility into the company’s immunology pipeline. Amgen announces Sjogren’s trial results
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing. The investment could give Amgen access to AI-driven genetic testing and molecular-data capabilities that may improve precision-medicine decisions and the design of genomically targeted clinical trials. Amgen backs Arboretum LifeSciences Series A
• Positive Sentiment: Amgen’s AMG 513 obesity study reached Phase 1 completion. While early-stage completion does not establish efficacy, the program adds another potential growth opportunity as the company competes in the weight-loss drug market. Amgen AMG 513 obesity trial update
• Neutral Sentiment: Cantor Fitzgerald maintained a Neutral rating, while another report cited a Neutral rating with a $400 price target. These views suggest analysts see limited near-term upside after the recent advance. Cantor Fitzgerald maintains Neutral rating
• Neutral Sentiment: A former Amgen commercial leader joined Entera Bio, a move relevant to Entera rather than Amgen and unlikely to materially affect AMGN’s fundamentals. Former Amgen leader joins Entera
• Negative Sentiment: Morgan Stanley lowered its price target to $359 while maintaining an Equal Weight rating, and Truist raised its target to $380 but kept a Hold rating. Both targets remain below the current share price, signaling valuation concerns and potential downside. Morgan Stanley lowers Amgen price target Truist raises Amgen price target

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.